aacr: continuous vs. intermittent dosing of braf/mek inhibitors in melanoma
Published 4 years ago • 20 plays • Length 5:23Download video MP4
Download video MP3
Similar videos
-
7:23
melanoma: braf/mek-inhibitors as adjuvant therapy
-
10:08
perspectives on braf and mek inhibitor combinations in braf-mutant melanoma
-
8:28
aacr: combination immunotherapy and targeted therapy for melanoma
-
8:24
management of side effects for braf/mek inhibitors for melanoma
-
9:24
anti-pd1 monotherapy or combination with ipi after braf/mek inhibitors in braf-mutant melanoma
-
8:47
braf/mek inhibitors in metastatic melanoma
-
1:28
jeffrey weber, md, phd: the impact of braf/mek inhibitors in melanoma
-
2:10
combined treatment with braf and mek inhibitors in metastatic melanomas with braf mutations
-
4:18
braf/mek inhibition as adjuvant treatment in melanoma
-
9:49
melanoma: nuances of braf/mek combinations in the front line
-
6:05
duration of dual braf-mek inhibition
-
1:06
jason luke, md: the impact of braf/mek inhibitors in melanoma
-
41:16
the side effects of braf/mek inhibitors and how to manage them
-
9:43
sequencing dual braf-mek inhibition and immunotherapy
-
1:33
dr. paul chapman on braf and mek inhibitor combination for advanced melanoma
-
16:59
targeted therapy-braf inhibitors and beyond
-
1:22
braf mutations and mek inhibitors
-
0:52
dr. kudchadkar on combining braf and mek inhibitors to treat melanoma
-
1:09
rationale for mek/braf combinations in melanoma